Scholarlink

<p>Perioperative systemic treatment is a&#xa0;central component of the multimodal treatment of muscle-invasive bladder cancer (MIBC) and significantly improves the prognosis of patients. Current guidelines recommend an interdisciplinary tumor board for treatment planning, with cisplatin-based chemotherapy, checkpoint inhibitors used alone, sequentially or in combination as well as antibody-drug conjugates combined with checkpoint inhibitors being employed. Recent data demonstrate that the combination of gemcitabine, cisplatin, and durvalumab extends event-free and overall survival. Relative contraindications should be individually weighed up to enable as many patients as possible to receive adequate treatment. In particular, combination therapies involving antibody-drug conjugates are expected to gain importance in perioperative systemic treatment in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Perioperative Therapie des muskelinvasiven Harnblasenkarzinoms

  • 期刊论文

  • 发表日期：

    2026年7月31日

查看全文
  • Günter Niegisch,
  • Camilla Grunewald

摘要

Perioperative systemic treatment is a central component of the multimodal treatment of muscle-invasive bladder cancer (MIBC) and significantly improves the prognosis of patients. Current guidelines recommend an interdisciplinary tumor board for treatment planning, with cisplatin-based chemotherapy, checkpoint inhibitors used alone, sequentially or in combination as well as antibody-drug conjugates combined with checkpoint inhibitors being employed. Recent data demonstrate that the combination of gemcitabine, cisplatin, and durvalumab extends event-free and overall survival. Relative contraindications should be individually weighed up to enable as many patients as possible to receive adequate treatment. In particular, combination therapies involving antibody-drug conjugates are expected to gain importance in perioperative systemic treatment in the future.